## Drug Monograph

| | |
|---|---|
| Drug/Drug Class: | **Macrilen™ (macimorelin acetate) granule for solution / Growth Hormone Secretagogue Receptor Agonist** |
| Prepared for: | MO HealthNet |
| Prepared by: | Conduent |

☒ **New Criteria** ☐ **Revision of Existing Criteria**

## Executive Summary

| | |
|---|---|
| **Purpose:** | The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use. |
| **Dosage Forms:** | Macrilen™ is available in 60 mg granules in a pouch for reconstitution in 120 ml of water, resulting in a solution of 0.5 mg/ml of macimorelin. |
| **Manufacturer:** | Distributed by: Strongbridge U.S. Inc., Trevose, PA 19053 |
| **Indications:** | Macrilen™ Sprinkle is indicated for the diagnosis of adult growth hormone deficiency. |
| **Costs:** | $4,500 per 60 mg pouch of Macrilen™. Wholesale Acquisition Cost |
| **Summary of Findings:** | MO HealthNet Division recommends Open Access status for this product. |
| **Status Recommendation:** | ☐ Prior Authorization (PA) Required ☒ Open Access<br>☐ Fiscal Edit ☐ PDL |
| **Type of PA Criteria:** | ☐ Increased Risk of ADE ☐ Under Solicitation<br>☐ Appropriate Indications ☒ No PA Required |

Prepared By: Luke Boehmer PharmD
Date: November 2, 2018

© 2018 Conduent Business Services, LLC All Rights Reserved.